Price W R, Johnson S T, Curtis B R
Department of Clinical Laboratory Sciences, Northern Michigan University, Marquette, Michigan 49855, USA.
Transfusion. 1999 Jul;39(7):756-62. doi: 10.1046/j.1537-2995.1999.39070756.x.
Identifying the isotype of an immunoglobulin (IgM vs. IgG) detected in a patient sample is especially important in anticipating the risk of hemolytic disease of the newborn. Currently, 2-mercaptoethanol (2-ME) treatment of a sample is used in the authors' laboratory to degrade IgM, and this is followed by retesting. This method has multiple drawbacks. The purpose of this study was to develop a flow cytometry (FC) assay that would replace the 2-ME treatment protocol (2-ME treatment).
A preliminary FC assay was developed, modified, and refined through the use of stock antibodies. Then, 10 samples containing antibodies were tested in parallel by the FC assay and 2-ME treatment.
When a 10-unit mean channel fluorescence change was used as an index of a positive result, the FC assay detected all isotypes identified by 2-ME treatment. The FC assay was also able to identify mixtures of isotypes. One antibody that had not reacted in conventional agglutination testing was detected by the FC assay. The amount of fluorescence and the agglutinating strength of the antibody did not parallel each other. In one case, this discrepancy may have reflected an antibody that was primarily IgA.
The FC assay appears to be as accurate as 2-ME treatment in differentiating IgG from IgM. The FC assay produces a positive endpoint for both isotypes, will identify IgA, requires less sample, and has no odor.
